Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: transcranial alternating current stimulation for Schizophrenia
This study is a randomly assigned, you will not be told which treatment you get, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the how well it works and mechanisms of individualized alpha-tACS on working memory.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are transcranial alternating current stimulation, or sham stimulation. The registry lists allocation as randomized. This study is a randomly assigned, you will not be told which treatment you get, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the how well it works and mechanisms of individualized alpha-tACS on working memory.
They plan to enroll about 30 people at Changsha. Taking part typically means using or being fitted with a device plus check-ins.
Official title (unrewritten)
Efficacy and Mechanisms of Transcranial Alternating Current Stimulation in Improving Working Memory in Patients With Schizophrenia
Interventions: transcranial alternating current stimulation, sham stimulation
Primary outcome (registry wording): Working Memory Accuracy
Who it is for (from inclusion criteria)
Ages 18 Years to 50 Years
Aged 18-50 years, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5)
Spatial span T-score \<40 on the MATRICS Consensus Cognitive Battery (MCCB)
Impaired functioning in daily activities
Who the registry excludes
Previously diagnosed with or comorbid any other DSM-5 mental disorder besides schizophrenia
Presence of significant mood symptoms or substance use disorder (other than caffeine and/or tobacco)
Presence of any contraindication to transcranial alternating current stimulation (tACS)
Received other forms of electrical or magnetic stimulation therapy within 1 month prior to enrollment
History or current presence of any major physical illness, neurological disorder, or traumatic brain injury that may affect brain structure or function
Pregnant or breastfeeding women, or women planning to become pregnant during the study period
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them.
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too.
This is a single-site, sham-controlled, randomly assigned trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07701343?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07701343?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.